The stock of Selecta Biosciences Inc (NASDAQ:SELB) reached all time high today, Nov, 24 and still has $27.34 target or 6.00% above today’s $25.79 share price. This indicates more upside for the $499.49M company. This technical setup was reported by Barchart.com. If the $27.34 PT is reached, the company will be worth $29.97 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. The stock increased 2.63% or $0.66 on November 23, hitting $25.79. About 10,846 shares traded hands. Selecta Biosciences Inc (NASDAQ:SELB) has risen 6.00% since October 25, 2016 and is uptrending. It has outperformed by 0.59% the S&P500.
Analysts await Selecta Biosciences Inc (NASDAQ:SELB) to report earnings on February, 9. After $-0.43 actual earnings per share reported by Selecta Biosciences Inc for the previous quarter, Wall Street now forecasts 18.60% negative EPS growth.
According to Zacks Investment Research, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States.”
More important recent Selecta Biosciences Inc (NASDAQ:SELB) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on May 26, 2016, also Globenewswire.com published article titled: “Selecta Biosciences Announces Pricing of Initial Public Offering”, Globenewswire.com published: “Selecta Biosciences Appoints Timothy C. Barabe to Board of Directors” on August 01, 2016. More interesting news about Selecta Biosciences Inc (NASDAQ:SELB) was released by: Seekingalpha.com and their article: “Selecta Biosciences IPO: Consider A Modest Allocation” with publication date: June 21, 2016.
SELB Company Profile
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Firm uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Firm operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment. The Company’s SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADA) in response to life-sustaining biologic drugs. The Company’s SVP technology has a range of applications to both manage biologic drugs and enable therapies. The Firm offers its product candidates in various programs, including SVP for immune tolerance and SVP for immune stimulation. The Company’s SVP for immune tolerance program includes Refractory and chronic tophaceous gout (SEL-212), Gene therapy for an autosomal recessive metabolic (ARM) disorder and Gene therapy for an X-linked metabolic (XLM) disorder. The Company’s SVP for immune stimulation includes Smoking cessation and relapse prevention (SEL-070), and human papillomavirus (HPV)-associated cancer (SEL-701). The Company’s antigen-specific SVP tolerance programs utilize SVP-Rapamycin, its biodegradable nanoparticle encapsulating the immunomodulator rapamycin. Rapamycin is a molecule approved for the prevention of organ rejection in kidney transplant patients. The Company’s SVP immune stimulation programs are designed to encapsulate an antigen and a toll-like receptor (TLR) agonist.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.